00 — Introduction
PRP treatment: effects, costs and procedure - a sober assessment
Medical professionals · Evidence-based overview · Status 2025/2026
PRP is not a miracle cure. It is also not one single, clearly standardised therapy. That is exactly where the problem starts: in practice, the same abbreviation is used for very different preparations, processing methods and treatment protocols. Anyone who asks only what a PRP treatment costs is asking too narrowly. The more relevant question is: what was prepared how, for which indication - and how much of that is actually clinically reliable?
01 — Basics
What is PRP, exactly?
PRP stands for platelet-rich plasma, meaning platelet-enriched plasma derived from autologous blood. What is meant is the processed liquid fraction of peripheral blood with a higher platelet concentration than baseline blood. Biologically, the idea is plausible: concentrating platelets, releasing growth factors and triggering local signalling for repair and remodelling processes. Clinically, however, that does not automatically translate into meaningful benefit for every indication.
Note
The real bottleneck is variability. Leukocyte-rich or leukocyte-poor, activated or not activated, single-spin or double-spin, different starting volume, different application scheme, different intervals - all of this changes the product. Reviews from 2024 to 2026 repeatedly identify this heterogeneity as the main reason why studies are difficult to compare and why results often diverge.
02 — Terminology
PRP, PRF and i-PRF: do not lump them together
In outward-facing communication, these terms are often mixed together. Professionally, that is sloppy. PRP is the injectable, platelet-enriched plasma fraction. PRF and i-PRF differ in fibrin structure, processing and release kinetics. A recent systematic review across medical fields describes a more prolonged release of growth factors for i-PRF, whereas PRP works differently. That does not mean i-PRF is automatically better. It only means this: evidence for PRP is not automatically evidence for PRF or i-PRF.
| Procedure |
Consistency |
Fibrin structure |
Release kinetics |
Typical use |
| PRP |
Liquid, injectable |
None / low |
Fast |
Injection, scalp infiltration |
| PRF |
Gel / membrane |
Fibrin scaffold |
Prolonged |
Surgery, wound healing |
| i-PRF |
Liquid, injectable |
Low fibrin |
Prolonged |
Injection (skin, hair) |
Key point
Evidence for one method cannot automatically be transferred to another. Always check studies against the specific product used.
03 — Practice
How does a PRP treatment work in practice?
The basic workflow is simple: indication, blood draw, centrifugation, separation of the target fraction and application to the defined area. In practice, this usually takes around 20 to 60 minutes depending on the area and protocol. For hair indications, publicly available practice descriptions often cite around 20 to 45 minutes per session.
Important
It sounds straightforward. Technically, it is not. Preanalytics already makes a difference: blood collection system, anticoagulant, time to centrifugation, speed or RCF, duration, fraction collection technique and application mode. Anyone turning this into a simple lifestyle procedure leaves out the part that determines reproducibility.
04 — Standardisation
Why PRP tubes, centrifuge and protocol are not a side issue
When studies show an effect, they do not show it for some vague form of "PRP", but for a specific protocol. A network meta-analysis of PRP protocols for knee osteoarthritis even suggests that results can differ depending on the preparation method. At the same time, the available data are not sufficient to declare one universal protocol for all indications. That is exactly why standardisation in practice is not a luxury, but a prerequisite for making treatment outcomes comparable at all.
Anyone working with PRP should view blood collection, tubes, centrifuge and preparation as one connected system rather than loose individual parts. A factual overview of PRP tubes in the practice workflow can be found at prpmed.de/en/prp-tubes.
Critical protocol parameters
| Parameter |
Relevance |
| Blood collection system / tube |
Defines the anticoagulant and baseline conditions |
| RCF (relative centrifugal force) & duration |
Determines cell distribution and platelet content in the final product |
| Single vs double centrifugation |
Influences purity and concentration factor |
| Activation (yes/no, by what) |
Controls the timing of growth factor release |
| Leukocyte status (L-PRP / P-PRP) |
Inflammation modulation, relevant depending on the indication |
| Number of sessions & intervals |
Described heterogeneously in clinical studies; should be defined according to the indication |
05 — Evidence
What does the evidence actually show?
Overview by indication
Androgenetic alopecia (hair density)
Meta-analysis 2025 (43 RCTs, 1,877 participants): moderate evidence for improved hair density and reduced hair loss. No consistent advantage for hair shaft thickness. Meta-analysis 2023 confirms a benefit for hair density after 3 and 6 months versus placebo.
Evidence: moderate
Facial rejuvenation (skin, wrinkles)
Systematic reviews 2025: indications of improvements in wrinkles and skin texture; side effects rare and transient. At the same time, there is marked heterogeneity in technique, dose and application form. Mixed evidence overall.
Evidence: mixed
Knee osteoarthritis
Partly symptomatic benefits in the short to medium term. Placebo-controlled meta-analysis 2025: rather weak efficacy up to 6 months, no clear advantage after 12 months. Other recent reviews are more positive - results depend heavily on the protocol.
Evidence: mixed
Achilles tendinopathy
Meta-analysis of RCTs 2025: no relevant benefit for pain or function compared with placebo. A clear negative result for this indication.
Evidence: low / negative
PRP vs i-PRF (across fields)
Systematic review 2025 across all medical fields: i-PRF tends to show more prolonged growth factor release. There is no automatism that one is superior to the other. Indication and protocol decide.
Evidence: preliminary
Protocol comparison in knee osteoarthritis
Network meta-analysis 2025: results vary depending on the preparation method. No universal protocol can be derived. Standardisation is a prerequisite for comparability.
Evidence: preliminary
PRP for hair loss: this is where the evidence is most usable
Within aesthetic applications, the evidence is currently most consistent for androgenetic alopecia. A 2025 meta-analysis of 43 randomised studies involving 1,877 participants found moderate evidence that PRP improves hair density, reduces hair loss and increases patient satisfaction. The paper did not show a robust benefit for hair thickness. An earlier meta-analysis from 2023 reached a similar conclusion: significant benefits for hair density after 3 and 6 months versus placebo, but no clearly placebo-superior effects for other hair parameters.
Precise wording
PRP may provide clinically relevant additional benefit for selected hair indications when used with a standardised protocol, but the evidence is not uniform and not equally strong for every regimen.
PRP in the face: plausible, partly positive, but methodologically much softer
For skin quality and facial rejuvenation, the evidence needs to be read more cautiously. A systematic review from 2025 found signals of improvement in wrinkles and skin texture in 9 clinical studies and 2 observational studies; side effects were rare and usually transient. At the same time, the authors describe major differences in technique, dose and application form and call for more robust studies. Another review from 2025 on PRP and PRF in facial rejuvenation also reports mixed evidence.
Plain language
Positive histology, patient satisfaction and smaller clinical improvements are not the same as robust, standardised, long-term outcome data. Anyone who mixes these things is selling hype as evidence.
Orthopaedics: highly variable depending on the indication
PRP is not a purely aesthetic topic. That is exactly why it makes sense to look beyond that field. For knee osteoarthritis, current reviews and meta-analyses show partly symptomatic benefits, especially in the short to medium term. At the same time, the clinical relevance remains disputed. A placebo-controlled meta-analysis from 2025 describes rather weak efficacy up to 6 months and no clear advantage after 12 months. Other recent reviews rate PRP more positively for knee osteoarthritis. That is not a contradiction, but a sign of how strongly results depend on study selection, comparator arm and protocol.
For other musculoskeletal indications, the picture is partly much worse. For Achilles tendinopathy, a 2025 meta-analysis of randomised studies came to a clearly sceptical conclusion: no relevant benefit for pain or function compared with placebo. That is exactly why it is professionally misleading to sell PRP as a generic regeneration therapy for almost anything. The indication decides.
06 — Costs
How much does a PRP treatment cost?
For people covered by statutory health insurance, PRP is usually a self-pay treatment in the outpatient setting. The German Federal Ministry of Health defines IGeL as services outside the catalogue of statutory health insurance benefits. gesund.bund.de also notes that such services are generally not covered by statutory insurers and usually have to be paid privately. In individual cases, insurers may provide exceptions or optional benefits. That is not the rule.
Guide prices (Germany, currently publicly visible)
| Indication / area |
Per session (single) |
Package examples |
| Face |
ca. 240 – 490 € |
3 sessions eye area: ~€1,200
4 sessions full face: ~€1,960 |
| Face + neck / additional areas |
also above €490 |
individual depending on the setting |
| Hair / scalp |
ca. 240 – 699 € |
2 sessions: ~€1,600
4 sessions: ~€2,800
6 sessions: ~€3,700 |
| Orthopaedics (joint etc.) |
from approx. €120 |
depending on combination and setting |
| Packages in general |
— |
3 sessions: ~€1,150 - €1,590
Premium settings: significantly higher |
Guide values based on publicly documented price lists and patient experience reports. Not binding market prices.
What do the costs actually depend on?
Cost factors
Indication and area · number of sessions · single session versus package · material system and preparation effort · combinations (e.g. microneedling, hyaluronic acid) · GOÄ-oriented billing or private invoice in individual cases
Anyone assessing prices seriously should therefore never compare only "PRP per session". Two offers can look equally expensive and still not be the same from a professional standpoint.
07 — Limits
Where are the limits of the method?
The biggest misunderstanding is a simple one: many people talk about PRP as if it were a standardised medicinal product. It is not. It is an umbrella term for differently prepared autologous blood products. Reviews from aesthetics, hair medicine and orthopaedics keep naming the same weaknesses:
| Weakness |
Consequence |
| Small sample sizes |
Low statistical power, poor generalisability |
| Short follow-up |
Long-term data are largely lacking |
| Lack of blinding |
Placebo effects not controlled sufficiently |
| Different endpoints |
Studies hardly comparable |
| Mixed combination therapies |
Isolated PRP effect unclear |
| Incomplete protocol description |
Reproducibility not ensured |
| Mixing up PRP / PRF / i-PRF |
Transferring evidence is professionally unsound |
Where too much is promised in practice
If people advertise guaranteed hair growth, clear skin rejuvenation or "regeneration" as a certain result, caution is warranted. The cleaner wording is different: there are indications with moderate to usable evidence, others with only preliminary data, and still others where high-quality studies do not show a convincing advantage. PRP is therefore neither quackery nor a cure-all. It is an indication-dependent method with technically sensitive implementation.
Practical relevance for professionals
PRP becomes professionally meaningful where three things come together: sound indication logic, a reproducible preparation protocol and honest counselling about the level of evidence. For hair indications, this is more tangible today than it was a few years ago. For facial applications, the method is interesting, but still supported much less cleanly from a methodological point of view. For musculoskeletal applications, the specific diagnosis matters more than the buzzword PRP.
Core requirement
Anyone who wants to use PRP in practice should not think about marketing first, but about standardisation: fixed blood collection, fixed tubes, fixed centrifuge, fixed RCF, fixed intervals, fixed documentation, fixed endpoints. Otherwise, each time you are in fact comparing a different product with a different target.
08 — Conclusion
An honest conclusion
PRP is not an empty trend, but neither is it a licence for bold promises. The strongest aesthetic evidence currently exists for hair indications. In facial rejuvenation, the data are encouraging, but still too heterogeneous for big claims. In orthopaedics, there are meaningful areas of use, but also clear negative findings. And when it comes to cost, the central question is not the cheapest or most expensive price, but whether indication, protocol and expectation management actually fit together.
09 — FAQ
Frequently asked questions
Q
How much does a PRP treatment cost per session?
As a rough guide, currently published price lists in Germany usually show around €240 to €699 per session, depending on area, indication and practice. Facial treatments in the examples found are often around €240 to €490, while hair treatments are frequently around €240 to €699. In orthopaedic settings, lower entry prices can also be found.
Q
How many sessions are common for PRP?
There is no fixed number. Publicly available practice information often mentions 2 to 4 initial treatments, sometimes followed by later maintenance sessions after about 6 to 12 months. That reflects practice reality more than hard evidence and should be determined according to the indication.
Q
Is PRP the same as PRF or i-PRF?
No. The methods are related, but not identical. They differ in preparation, fibrin structure and the release of growth factors. Evidence from PRP studies should therefore not automatically be transferred to PRF or i-PRF.
Q
How robust is the evidence for hair loss?
Compared with other aesthetic PRP applications, this is where the evidence is most usable. Current meta-analyses show benefits for hair density and hair loss, but no consistently placebo-superior effects across all hair parameters. Study quality is better than in some other fields, but still not ideal.
Q
Does PRP really help in the face?
Possibly, yes. Clearly and standardly proven, no. Reviews indicate improvements in skin texture, fine wrinkles, hydration and overall skin appearance. At the same time, the data are heterogeneous and the protocols vary widely. PRP in the face is therefore better described as "promising with open questions" than as "clearly established".
Q
Does statutory health insurance cover PRP?
Usually not. In outpatient care, PRP often falls into the category of self-pay services. Some insurers may offer exceptions or voluntary benefits in individual cases, but private payment is the rule.
Q
Why are PRP tubes and the centrifuge so important professionally?
Because they co-define the product. Different tubes, anticoagulants, centrifugation parameters and collection schemes lead to different PRP profiles. That can influence the comparability of results and possibly the clinical effect as well.
Q
What side effects are typical?
Overall, the literature describes PRP as fairly well tolerated. Typical reactions are local and usually temporary, such as bruising, oedema, redness or a feeling of pressure or tension at the injection site. Current reviews do not describe severe adverse events as a frequent pattern.
10 — References
Study references
-
01
Anitua E, Tierno R, Alkhraisat MH. Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence.
Dermatology and Therapy. 2025.
PubMed ↗
-
02
Zhang X, Ji Y, Zhou M et al. Platelet-Rich Plasma for Androgenetic Alopecia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Journal of Cutaneous Medicine and Surgery. 2023.
PubMed ↗
-
03
Rodríguez-Castro MJ, Cortés-Rodríguez AE. Efficacy of platelet-rich plasma in facial rejuvenation: A systematic review.
Enfermería Clínica. 2025.
PubMed ↗
-
04
Qin N, Kochheiser M, Akosman I et al. Systematic Review of Platelet-Rich Plasma and Platelet-Rich Fibrin in Facial Rejuvenation.
Annals of Plastic Surgery. 2025.
PubMed ↗
-
05
Asubiaro J, Avajah F. Platelet-Rich Plasma in Aesthetic Dermatology: Current Evidence and Future Directions.
Cureus. 2024.
PMC ↗
-
06
Wang C, Yao B. Efficacy and safety of platelet-rich plasma injections for the treatment of knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.
European Journal of Medical Research. 2025.
PubMed ↗
-
07
Auroux M, Debionne T, Mainbourg S, Chapurlat R. Efficacy of intra-articular platelet-rich plasma compared with placebo in knee osteoarthritis: A systematic review and meta-analysis.
Joint Bone Spine. 2025.
PubMed ↗
-
08
Barreto ESR, Antunes Júnior CR, Silva IC et al. Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials.
Clinical Orthopaedics and Related Research. 2025.
PubMed ↗
-
09
Yu D, Zhao J, Zhao K. The efficacy of platelet-rich plasma preparation protocols in the treatment of osteoarthritis: a network meta-analysis of randomized controlled trials.
Journal of Orthopaedic Surgery and Research. 2025.
BioMedCentral ↗
-
10
Farshidfar N, Amiri MA, Estrin NE et al. Platelet-rich plasma (PRP) versus injectable platelet-rich fibrin (i-PRF): A systematic review across all fields of medicine.
Periodontology 2000. 2025.
PubMed ↗
